Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.65 |
| ▸ | PAM | P19021 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181324 | 0.98 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2145671 | 0.98 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2183449 | 0.98 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2217057 | 0.98 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL31112831 | 0.98 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL355564 | 0.98 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2182828 | 0.98 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL8680864 | 0.93 | — | — | |
| Chloroform SCHEMBL8310130 | 0.92 | DGKA (0.57) | DGKAPAMTSHRMAPTLMNA | |
| Chloroform SCHEMBL8307778 | 0.90 | DGKA (0.60) | DGKAPAMTSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066376-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES INC (US) | 2025-02-27 | — | — | US | disclosed |
| CN-106748748-B | Preparation method and intermediate of brivaracetam | 成都国为生物医药有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LTD (IE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LTD (IE) | 2015-12-31 | — | — | US | disclosed |
| US-9102618-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-9102618-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| CN-101479279-B | Penan prodrugs | PFIZER PROD INC | 2011-08-17 | — | — | CN | disclosed |
| US-4425341-A | CEPHALOSPORING | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1984-01-10 | — | — | US | disclosed |
| US-4423213-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
| US-4409214-A | Including cefixime; antibiotics | FUJISAWA PHARMACEUTICAL, CO., LTD. (JP) | 1983-10-11 | — | — | US | disclosed |
| US-4400379-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-08-23 | — | — | US | disclosed |
| US-4399133-A | ADMINISTERING, INFECTIONS | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-08-16 | — | — | US | disclosed |
| US-4393059-A | BACTERICIDAL CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-07-12 | — | — | US | disclosed |
| US-4313956-A | Novel sypathomimetic amine prodrugs | INTERX RESEARCH CORP. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4304770-A | Syn-isomer of 3,7-disubstituted-3-cephem-4-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| US-4294960-A | 7-[2-(2-Aminothiazol-4-yl)-2-cyclopentyloxyiminoacetamido]-3-cephem-4-carboxylic acid (synisomer) | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-10-13 | — | — | US | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066376-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRL1, OPRM1, OPRD1 | DGKA 3915/4885PAM 68/4885TSHR 209/4885 |
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.